Home / Psoriasis (page 10)

Psoriasis

Here you will find the latest clinical research on psoriasis.

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis (Ixora-peds)

  Purpose The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis. Condition Intervention Phase Plaque Psoriasis Drug: Ixekizumab Drug: Placebo Phase 3 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, …

Read More »

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis (PsaBio)

  Purpose The purpose of this study is to evaluate treatment retention in psoriatic arthritis participants with STELARA or tumor necrosis factor alpha inhibitor (TNFi) therapies in relation to effectiveness, safety, benefit/risk and to examine clinical response. Condition Intervention Psoriatic Arthritis Drug: No Intervention Study Type: Observational Study Design: Observational …

Read More »

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (VIP-S)

  Purpose This study will evaluate the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments. Condition Intervention Phase Chronic Plaque Psoriasis Biological: Secukinumab 300 mg Biological: Placebo Phase 4 Study …

Read More »

Apremilast Pregnancy Exposure Registry

  Purpose The purpose of the Apremilast Pregnancy Exposure Registry is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the safety of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal apremilast exposure on infant health status through one year of …

Read More »

Effect of Secukinumab in the Treatment of Psoriatic Arthritis (SATURN)

  Purpose The investigators propose an open label pragmatic clinical and laboratory study designed to investigate, in detail, the clinical and molecular effects of Interleukin 17 (IL-17) and inhibition of IL-17 with secukinumab, on neutrophil function in vitro and ex vivo. As secondary, exploratory objectives, the investigators will utilise the …

Read More »

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

  Purpose The main purpose of the current study will be to provide real – world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis. Condition Psoriasis Study Type: Observational [Patient Registry] Study Design: Observational Model: CohortTime Perspective: Prospective …

Read More »

Initial Treatment With Golimumab in Early PsA

  Purpose The investigators will perform a 22-week randomized, double-blind, placebo-controlled trial of golimumab + methotrexate (MTX) versus methotrexate alone in methotrexate-naïve patients with Psoriatic Arthritis (PsA). Afterwards, a 28 week open label phase with methotrexate alone is started. Golimumab will be discontinued. Hypotheses: First, the investigators hypothesize that initiation …

Read More »

A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium (OTELO)

  Purpose OTELO is a national (Belgium), multicentre, prospective, non-interventional, post-marketing study. The study will include a representative sample of approximately 250 patients with moderate-to-severe plaque psoriasis for whom the treating dermatologist has decided to begin apremilast treatment in accordance with the local label and reimbursement criteria. Patients may be …

Read More »

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

  Purpose The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches). Condition Intervention Phase Psoriasis Drug: CNTO …

Read More »

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis (EXCEED 1)

  Purpose The purpose of this study is to compare the safety and efficacy of secukinumab monotherapy and adalimumab monotherapy in patients with active psoriatic arthritis who are naïve to biologic therapy and are intolerant or having inadequate response to conventional DMARDs Condition Intervention Phase Psoriatic Arthritis Biological: Secukinumab Biological: …

Read More »